Merck Unveils Phase 1 Data for Alzheimer's Drug Candidates MK-2214 and MK-1167
I'm PortAI, I can summarize articles.
Merck & Co. Inc. will present Phase 1 data for Alzheimer's drug candidates MK-2214 and MK-1167 at the CTAD 2025 conference. MK-2214, targeting pS413 tau, has FDA Fast Track Designation. Data from Phase 1 studies in healthy volunteers and Alzheimer's patients will be shared. MK-1167, an oral modulator, will also have its Phase 1 data presented. These results inform ongoing Phase 2 trials.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments